

Quantity Limit

Antiviral for the Treatment of COVID-19

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Paxlovid for Emergency Use Authorization	nirmatrelvir tablets and ritonavir tablets
Paxlovid	nirmatrelvir tablets and ritonavir tablets

Indications

FDA-Approved Indications

Paxlovid is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Limitations of Use

- Paxlovid is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

Emergency Use Authorization

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of PAXLOVID for the treatment of adults and pediatric patients 12 years of age and older weighing at least 40 kg with mild-to-moderate coronavirus disease 2019 (COVID-19) and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Limitations of Use

- Paxlovid is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

Initial Limit Quantity

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed.

These drugs are for short-term acute use.

Drug	Limit
Paxlovid For Emergency Use Authorization (300 mg nirmatrelvir; 100 mg ritonavir)	60 tablets (2 cartons containing 30 tablets (10 doses) each of 2 tablets of nirmatrelvir 150 mg and 1 tablet of ritonavir 100 mg) / 30 days
Paxlovid (300 mg nirmatrelvir; 100 mg ritonavir)	60 tablets (2 cartons containing 30 tablets (10 doses) each of 2 tablets of nirmatrelvir 150 mg and 1 tablet of ritonavir 100 mg) / 30 days
Paxlovid For Emergency Use Authorization (150 mg nirmatrelvir; 100 mg ritonavir)	40 tablets (2 cartons containing 20 tablets (10 doses) each of 1 tablet of nirmatrelvir 150 mg and 1 tablet of ritonavir 100 mg) / 30 days
Paxlovid (150 mg nirmatrelvir; 100 mg ritonavir)	40 tablets (2 cartons containing 20 tablets (10 doses) each of 1 tablets of nirmatrelvir 150 mg and 1 tablet of ritonavir 100 mg) / 30 days
Paxlovid (300 mg nirmatrelvir; 100mg ritonavir) (Day 1) (150 mg nirmatrelvir; 100 mg ritonavir) (Days 2-5)	22 tablets (2 cartons containing 11 tablets (5 doses) each of 2 tablets of nirmatrelvir 150 mg and 1 tablet of ritonavir 100 mg for day 1 and 1 tablet of nirmatrelvir 150 mg and 1 tablet of ritonavir 100 mg for days 2-5) / 30 days

References

- Paxlovid [package insert]. New York, NY: Pfizer Inc.; January 2025.
- Paxlovid [Emergency Use Authorization Fact Sheet for Health Care Providers]. New York, NY: Pfizer Inc.; January 2025.
- Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed August 8, 2024.
- Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/08/2024).

Reference number(s)
5099-H

Document History

Written by: UM Development (VLS)

Date Written: 12/2021

Revised: VLS 05/2022, 11/2022 (no clinical changes), 10/2023 (added FDA approved Paxlovid), 11/2023 (no clinical changes), 08/2024 (no clinical changes), 01/2025 (added Paxlovid for severe renal impairment)

Reviewed: Medical Affairs: (CHART) 05/2022, 12/01/2022, 11/30/2023, 08/29/2024, 02/20/2025

External Review: 12/2021, 06/2022, 02/2023, 02/2024, 12/2024, 04/2025 (FYI)